Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 30, 2025
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
GlobeNewswire
·
April 30, 2025
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that …
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
GlobeNewswire
·
April 30, 2025
Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow …
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
GlobeNewswire
·
April 30, 2025
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on …
Cellectar Announces Plan to Explore Strategic Alternatives
GlobeNewswire
·
April 30, 2025
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today …
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
GlobeNewswire
·
April 30, 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …
Folia Health and Inspire are Partnering to Bring Personalized Home Health Observations to the Forefront of Patient Focused Drug Development Research
GlobeNewswire
·
April 30, 2025
BOSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Folia Health, the pioneer of patient-driven Home Reported Outcomes (HRO), has partnered with Inspire, the world's leading online health community and real-world data platform, to uniquely empower patients and …
BioAtla to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
GlobeNewswire
·
April 30, 2025
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a. …
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 30, 2025
KIRKLAND, Wash., April 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences: Event: BofA …
Solid Biosciences to Participate at The Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, …
Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology’s Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire
·
April 30, 2025
BERKELEY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its president and chief scientific officer, Wesley Jackson, Ph.D., will present a company and …
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will …
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
GlobeNewswire
·
April 30, 2025
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced …
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
GlobeNewswire
·
April 30, 2025
NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients …
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
GlobeNewswire
·
April 30, 2025
SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a …
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
GlobeNewswire
·
April 30, 2025
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians …
Commure’s AI-Powered Ambient Suite Achieves Epic Toolbox Designation for Ambient Voice Recognition
GlobeNewswire
·
April 30, 2025
MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company transforming the industry with advanced AI solutions, announced today that its Ambient Suite is now integrated with Epic Haiku as part of Toolbox …
Intercept Announces Data to be Presented at Digestive Disease Week 2025
GlobeNewswire
·
April 30, 2025
MORRISTOWN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Intercept), part of the Alfasigma Group, today announced 11 submitted abstracts have been accepted for presentation at Digestive Disease Week 2025, including oral …
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
April 30, 2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus …
electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
GlobeNewswire
·
April 30, 2025
ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of …